TY - JOUR
T1 - The Fukuoka Kidney disease Registry (FKR) Study
T2 - design and methods
AU - Fukuoka Kidney disease Registry (FKR) Study Collaboration Group
AU - Tanaka, Shigeru
AU - Ninomiya, Toshiharu
AU - Fujisaki, Kiichiro
AU - Yoshida, Hisako
AU - Nagata, Masaharu
AU - Masutani, Kosuke
AU - Tokumoto, Masanori
AU - Mitsuiki, Koji
AU - Hirakata, Hideki
AU - Fujimi, Satoru
AU - Kiyohara, Yutaka
AU - Kitazono, Takanari
AU - Tsuruya, Kazuhiko
N1 - Publisher Copyright:
© 2016, Japanese Society of Nephrology.
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Background: Chronic kidney disease (CKD) is an established independent risk factor for progression to end-stage renal disease (ESRD) and incidence of cardiovascular disease (CVD). The onset and progression of CKD are associated with both genetic predisposition and various lifestyle-related factors, but little is known about the influence of genetic-environmental interactions on the incidence of ESRD or CVD in patients with CKD. Methods: The Fukuoka Kidney disease Registry (FKR) Study is designed as one of the largest prospective, multicenter, observational cohort studies in non-dialysis dependent CKD patients. The FKR Study aims to enroll approximately 5000 individuals at multiple clinical centers and follow them for up to at least 5 years. At baseline, subjects enrolled in the FKR Study will fill out extensive lifestyle-related questionnaires. Further, their health status and treatments will be monitored annually through a research network of nephrology centers. Blood and urine samples, including DNA/RNA, will be collected at the time of enrolment and every 5-years follow-up. Conclusions: The FKR Study will provide many insights into the onset and progression of CKD, which will suggest hypothesis-driven interventional clinical trials aimed at reducing the burden of CKD. The features of the FKR Study may also facilitate innovative research to identify and validate novel risk factors, including genetic susceptibility and biomarkers, using biomaterials by high-throughput omics technologies.
AB - Background: Chronic kidney disease (CKD) is an established independent risk factor for progression to end-stage renal disease (ESRD) and incidence of cardiovascular disease (CVD). The onset and progression of CKD are associated with both genetic predisposition and various lifestyle-related factors, but little is known about the influence of genetic-environmental interactions on the incidence of ESRD or CVD in patients with CKD. Methods: The Fukuoka Kidney disease Registry (FKR) Study is designed as one of the largest prospective, multicenter, observational cohort studies in non-dialysis dependent CKD patients. The FKR Study aims to enroll approximately 5000 individuals at multiple clinical centers and follow them for up to at least 5 years. At baseline, subjects enrolled in the FKR Study will fill out extensive lifestyle-related questionnaires. Further, their health status and treatments will be monitored annually through a research network of nephrology centers. Blood and urine samples, including DNA/RNA, will be collected at the time of enrolment and every 5-years follow-up. Conclusions: The FKR Study will provide many insights into the onset and progression of CKD, which will suggest hypothesis-driven interventional clinical trials aimed at reducing the burden of CKD. The features of the FKR Study may also facilitate innovative research to identify and validate novel risk factors, including genetic susceptibility and biomarkers, using biomaterials by high-throughput omics technologies.
UR - http://www.scopus.com/inward/record.url?scp=84976287048&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84976287048&partnerID=8YFLogxK
U2 - 10.1007/s10157-016-1294-4
DO - 10.1007/s10157-016-1294-4
M3 - Article
C2 - 27339444
AN - SCOPUS:84976287048
SN - 1342-1751
VL - 21
SP - 465
EP - 473
JO - Clinical and Experimental Nephrology
JF - Clinical and Experimental Nephrology
IS - 3
ER -
